9. Cardea Solo diagnoses arrhythmias
FDA recently cleared the Cardiac Insight Cardea Solo wearable electrocardiogram sensor.
Cardea Solo has proprietary algorithms that can accurately detect transient, difficult-to-diagnose or asymptomatic arrhythmias, according to the company. It gives physicians full access to timely, definitive data and a more timely diagnosis of arrhythmia.
Those who have transient symptoms like palpitations, dizziness, anxiety, fatigue, syncope, pre-syncope, light-headedness and shortness of breath – or are at risk of atrial fibrillation – may benefit from using the Cardea Solo.
The wearable can analyze a variety of beats and rhythms, including pauses, premature atrial contractions, supraventricular tachycardia, atrial fibrillation, tachycardia, bradycardia, premature ventricular contractions, couplets, triplets, ventricular tachycardia, bigeminy and trigeminy.
The Cardea Solo is small, lightweight, water-resistant and disposable and can be worn under normal clothing. It can also monitor and record ECG signals and occurrences of patient symptoms for up to 7 days.
Kirkland, Wash.-based Cardiac Insight recently won FDA 510(k) clearance for the wearable ECG sensor.